EAA-090 is being developed for the treatment of neuropathic pain associated with diabetic neuropathy. It is a selective antagonist that binds competitively to the glutamate site of the N-methyl-D-aspartate (NMDA) receptor. This study will assess the safety and efficacy of 3 fixed oral doses of EAA-090 compared with placebo in subjects with neuropathic pain associated with diabetic neuropathy.
Inclusion Criteria: * Women of childbearing potential must have a negative serum pregnancy test result at screening * Diabetes mellitus (type I or II) that is controlled by oral or parenteral hypoglycemic agents or diet * Diagnosis of painful diabetic distal symmetric sensory/motor polyneuropathy Exclusion Criteria: * Pregnancy, lactation, or plans to become pregnant during the study * Depo-Provera or oral contraceptives that have been taken for less than 1 month before study day 1 if not using another medically accepted form of birth control * History of multiple drug allergies that may put the subject at greater risk during study participation in the opinion of the investigator